[go: up one dir, main page]

EP1341549A2 - Traitement combine de maladies dependantes des oestrogenes - Google Patents

Traitement combine de maladies dependantes des oestrogenes

Info

Publication number
EP1341549A2
EP1341549A2 EP01990699A EP01990699A EP1341549A2 EP 1341549 A2 EP1341549 A2 EP 1341549A2 EP 01990699 A EP01990699 A EP 01990699A EP 01990699 A EP01990699 A EP 01990699A EP 1341549 A2 EP1341549 A2 EP 1341549A2
Authority
EP
European Patent Office
Prior art keywords
cancer
aromatase inhibitor
lhrh agonist
triptorelin
exemestane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01990699A
Other languages
German (de)
English (en)
Inventor
Dinesh Purandare
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co LLC
Original Assignee
Pharmacia and Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co filed Critical Pharmacia and Upjohn Co
Publication of EP1341549A2 publication Critical patent/EP1341549A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Definitions

  • the present invention relates to a combination therapy for treating estrogen dependent cancers in susceptible mammals, including humans, comprising the steps of inhibiting hormone output of their testis or ovaries, respectively, and administering to said mammal at least one aromatase inhibitor.
  • LHRH agonists Luteinizing Hormone Releasing Hormone agonists
  • U.S. Pat. No. 4,775,660 relates to the treatment of female breast cancer by use of a combination therapy comprising administering an antiandrogen and an antiestrogen to a female after the hormone output of her ovaries has been blocked by chemical or surgical means.
  • U.S. Pat. No. 4,775,661 relates to the treatment of female breast cancer by use of a therapy comprising administering to a female, after the hormone output of her ovaries has been blocked by chemical or surgical means, an antiandrogen and optionally an inhibitor of sex steroid biosynthesis.
  • U.S. Pat. No. 4,760,053 describes the treatment of selected sex steroid dependent cancers which combines a LHRH agonist and/or an antiandrogen and/or an antiestrogen and/or at least one inhibitor of sex steroid biosynthesis.
  • prostatic adenocarcinoma, benign prostatic hypertrophy and hormone-dependent mammary tumors may be treated with various LH-RH agonists and that prostate adenocarcinoma and benign hypertrophy may be treated by use of various LHRH agonists and an antiandrogen.
  • U.S. Pat. No. 5,550,107 relates to a treatment of female breast and endometrial cancer by use of a therapy comprising administering to a female after the hormone output of the ovaries has been blocked an antiestrogen and at least one compound selected, e.g., from an androgen, a progestin, at least one inhibitor of sex steroid biosynthesis and one inhibitor of prolactin secretion.
  • a therapy comprising administering to a female after the hormone output of the ovaries has been blocked an antiestrogen and at least one compound selected, e.g., from an androgen, a progestin, at least one inhibitor of sex steroid biosynthesis and one inhibitor of prolactin secretion.
  • the invention provides a method for treating an sex-steroid dependent cancer in a mammal in need of such treatment, including humans, comprising administering simultaneously, separately or sequentially to said mammal an aromatase inhibitor and a
  • LHRH agonist or antagonist in amounts and close in time sufficient to achieve a therapeutically useful effect, and wherein, when the cancer is breast cancer, and a) the LHRH agonist is triptorelin, then the aromatase inhibitor is other than formestane, b) the LHRH agonist is goserelin, then the aromatase inhibitor is other than vorozole or formestane, or c) the
  • LHRH agonist is leuprorelin, then the aromatase inhibitor is other than fadrozole.
  • Such human is a premenopausal woman.
  • the present invention also provides the use of an aromatase inhibitor in the manufacture of a medicament for treating a sex steroid dependent cancer in a mammal, including humans, undergoing a simultaneous, separate or sequential treatment with a LHRH agonist or antagonist, and wherein, when the cancer is breast cancer, and a) the LHRH agonist is triptorelin, then the aromatase inhibitor is other than formestane, b) the LHRH agonist is goserelin, then the aromatase inhibitor is other than vorozole or formestane, or c) the LHRH agonist is leuprorelin, then the aromatase inhibitor is other than fadrozole.
  • the invention also provides a product containing an aromatase inhibitor and a LHRH agonist or antagonist as a combined preparation for simultaneous, separate or sequential use in treating sex steroid dependent cancers, and wherein, when the cancer is breast cancer, and a) the
  • LHRH agonist is triptorelin, then the aromatase inhibitor is other than formestane, b) the
  • LHRH agonist is goserelin, then the aromatase inhibitor is other than vorozole or formestane, or c) the LHRH agonist is leuprorelin, then the aromatase inhibitor is other than fadrozole.
  • the estrogen-dependent cancers that can by treated by the combined therapy method provided by the present invention are cancers known in the art as "sex steroid dependent cancers". Examples of such cancers are testicular cancer, prostate cancer, ovarian cancer, pancreatic cancer, uterine cancer, celomic epithelial carcinoma, germ cell ovarian cancer, fallopian tube ovarian cancer, breast cancer and lung cancer.
  • such cancers are prostate cancer, ovarian cancer and breast cancer, in particular breast cancer in a premenopausal woman.
  • aromatase inhibitors according to the invention are exemestane, formestane, fadrozole, letrozole, vorozole and anastrozole, preferably exemestane, anastrozole and letrozole, in particular exemestane.
  • aromatase inhibitor is meant to comprise both a single aromatase inhibitor or a mixture of two or more, preferably two, aromatase inhibitors as defined above.
  • the single aromatase inhibitor, or one of the component of the mixture is exemestane.
  • LHRH agonists according to the invention are, e.g., leuprorelin, deslorelin, triptorelin, buserelin, nafarelin, goserelin, avorelin, histerelin, compound PTL 03001
  • LHRH agonists are triptorelin and goserelin, or a pharmaceutically acceptable salt thereof, in particular triptorelin or a pharmaceutically acceptable salt thereof.
  • LHRH antagonists are e.g. cetrorelix, abarelix, ramorelix, teverelix, ganirelix, compounds A 75998 (Acetyl-D-(2-naphthyl)alanyl-D-(4- chlorophenyl)alanyl-D-(3- ⁇ yridyl)alanyl-seryl-(N-methyl)tyrosyl-N6-(nicotinoyl)-D-lysyl- leucyl-N6-(isopropyl)lysyl-propyl-D-alaninamide) and A 84861 (Tetrahydrofuran-2-(S)- ylcarbonyl-glycyl-D-(2-naphthyl)alanyl-D-(4-cholro)phenylalanyl-D-(3-pyridyl)-alanyl-L-(N
  • the inventors of the present invention have also found that treatment of the above mentioned sex steroid-dependent disorders by combined administration of a therapeutically effective amount of an aromatase inhibitor and a therapeutically effective amount of a LHRH agonist or antagonist, can produce a therapeutic effect which is greater than that obtainable by single administration of a therapeutically effective amount of sole LHRH agonist or antagonist. Most importantly, they have found that such newly obtained therapeutic effect is not paralleled by the toxic effects, otherwise caused by single administration of either therapeutically effective amounts of an aromatase inhibitor or, of the LHRH agonist or antagonist.
  • treating means in particular “controlling the growth” of the neoplasm, namely slowing, interrupting, arresting, stopping or reversing the neoplasm formation and it does not necessarily indicate a total elimination of the neoplasm.
  • the aromatase inhibitor and the LHRH agonist or antagonist can be administered in any form or mode which makes the compounds bioavailable in effective amounts, including oral and parenteral routes.
  • admimstered or “administering” as used herein is meant any acceptable manner of administering a drug to a patient which is medically acceptable including parenteral and oral administration.
  • parenteral is meant intravenous, subcutaneous, intradermal or intramuscular administration.
  • Oral administration includes administering one or both of the constituents of the combined preparation in a suitable oral form such as, e.g., tablets, capsules, suspensions, solutions, emulsions, powders, syrups and the like.
  • a suitable oral form such as, e.g., tablets, capsules, suspensions, solutions, emulsions, powders, syrups and the like.
  • the actual preferred method and order of administration of the combined preparations of the invention can vary according to, inter alia, the particular pharmaceutical formulation of the aromatase inhibitor being utilized, the particular pharmaceutical formulation of the LHRH agonist or antagonist being utilized, the particular sex steroid-dependent cancer to be treated and the particular patient being treated.
  • the term "close in time” means that in the combined method of treatment according to the subject invention, the aromatase inhibitor can be admimstered simultaneously with the LHRH agonist or antagonist or the compounds can be administered sequentially, in either order.
  • the compounds are administered in such a way that both inhibition of hormone output of mammal's testis or ovaries and inhibition of aromatase enzyme are contemporaneously provided, and thus a therapeutically useful effect is achieved.
  • Dosage The dosage ranges for the administration of the combined preparation can vary with the age, condition and extent of the disease in the patient and can be determined by one of skill in the art.
  • the dosage regimen must therefore be tailored to the particular of the patient's conditions, response and associated treatments in a manner which is conventional for any therapy, and can be adjusted in response to changes in conditions and/or in light of other clinical conditions.
  • An effective amount of an aromatase inhibitor antitumor agent can vary from about 0.5 to about 500 mg per dose 1-2 times a day.
  • Fadrozole can be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2 mg.
  • Letrozole for example, can be admimstered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2.5 mg.
  • Formestane for example, can be administered parenterally in a dosage range varying from about 250 to about 500 mg, and particularly, from about 250 to about 300 mg.
  • Anastrozole for example, can be administered orally in a dosage range varying from about 0.5 to about 10 mg, and particularly, from about 1 to about 2 mg.
  • Exemestane for instance can be administered orally in a dosage range varying from about 5 mg daily to about 600 mg daily, in particular from about 10 to about 50, more particularly from about 10 to about 25 mg daily, or parenterally in a dosage ranging from about 50 to about 500 mg per injection.
  • An effective amount of LHRH agonist or antagonist is in general the one commonly used in therapy for such compounds.
  • Goserelin can be administered as goserelin acetate by subcutaneous administration of slow release goserelin at a dosage from about 3 to about 12 mg.
  • Triptorelin can be administered for instance as triptorelin pamaote by intramuscular administration in the form of a depot formulation at a dosage from about 3 to about 20 mg, in such a way that there is an interval of about 1, 2, 3 or 4 months between each administration.
  • triptorelin pamoate can be administered intramuscularly in the form of microparticles as described in US Pat. No. 5,225,205 and US Pat. No. 5,776,885, and more specifically as 1- month depot formulation 3.75 mg.
  • abarelix can be administered as single intramuscular administration of slow release abarelix 10 to 200 mg every 2 weeks or every month.
  • the invention provides a method of treating a sex steroid dependent cancer selected from ovarian and breast cancer in a pre-menopausal woman in need of such treatment, comprising administering substantially simultaneously to said woman exemestane and triptorelin or a pharmaceutically acceptable salt thereof, in amounts and close in time sufficient to achieve a therapeutically useful effect.
  • substantially simultaneous means that exemestane and triptorelin are administered in such a way that both inhibition of hormone out-put of her ovaries and inhibition of aromatase enzyme are contemporaneously provided, and thus a therapeutically useful effect is achieved.
  • exemestane in the manufacture of a medicament for treating a sex steroid dependent cancer selected from ovarian and breast cancer in premenopausal woman, undergoing a substantially simultaneous treatment with triptorelin or a pharmaceutically acceptable salt thereof.
  • breast cancer is treated.
  • triptorelin pamoate salt are administered substantially simultaneously, as herein described, to achieve a therapeutically useful effect.
  • triptorelin pamoate can be administered as a sustained release formulation, in such a way that there is an interval from about 1 to 4 months between each administration, e.g. in the form of 1 month depot 3.75 mg formulation, as described in US Pat. No. 5,225,205 and US Pat. No. 5,776,885.
  • Exemestane can be administered parenterally at a dosage ranging from about 50 to about 500 mg per injection, or orally at a dosage from about 10 to about 25 mg daily.
  • kits or single packages containing the pharmaceutical compositions useful for the combination treatment of the selected sex steroid- dependent cancers discussed above.
  • the kits or packages can also contain instructions to use the pharmaceutical compositions in accordance with the present invention.
  • a kit according to the present invention provides an exemestane 25 mg oral or 50-500 mg parenteral composition and a triptorelin 1 month depot formulation 3.75 mg.
  • a pharmaceutical composition for intramuscular administration containing triptorelin pamoate in the form of a depot formulation can be prepared as described in US Pat. No. 5,225,205 and US Pat. No. 5,776,885.
  • a pharmaceutical composition containing exemestane can be prepared, ple, according to US Pat. No. 4,808,616.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une thérapie combinée servant à traiter des cancers dépendant des oestrogènes chez des mammifères, y compris les humains, ce qui consiste à inhiber la sortie hormonale de leurs testicules ou de leurs ovaires et à administrer à ces mammifères au moins un inhibiteur d'aromatase.
EP01990699A 2000-11-16 2001-11-06 Traitement combine de maladies dependantes des oestrogenes Withdrawn EP1341549A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71460500A 2000-11-16 2000-11-16
US714605 2000-11-16
PCT/US2001/043847 WO2002039995A2 (fr) 2000-11-16 2001-11-06 Traitement combine de maladies dependantes des oestrogenes

Publications (1)

Publication Number Publication Date
EP1341549A2 true EP1341549A2 (fr) 2003-09-10

Family

ID=24870727

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01990699A Withdrawn EP1341549A2 (fr) 2000-11-16 2001-11-06 Traitement combine de maladies dependantes des oestrogenes

Country Status (16)

Country Link
EP (1) EP1341549A2 (fr)
JP (1) JP2004536022A (fr)
KR (1) KR20030051828A (fr)
CN (1) CN1498112A (fr)
AU (1) AU2002230464A1 (fr)
BR (1) BR0115423A (fr)
CA (1) CA2428249A1 (fr)
CZ (1) CZ20031349A3 (fr)
EA (1) EA200300572A1 (fr)
IL (1) IL155817A0 (fr)
MX (1) MXPA03004195A (fr)
NO (1) NO20032206L (fr)
NZ (1) NZ525720A (fr)
PL (1) PL365904A1 (fr)
WO (1) WO2002039995A2 (fr)
ZA (1) ZA200303669B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2410906C (fr) 2000-06-02 2012-10-02 Board Of Regents, The University Of Texas System Conjugues ethylenedicysteine (ec)-medicament
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
GB0506759D0 (en) * 2005-04-02 2005-05-11 Medical Res Council Combination treatment methods
EP1891964A1 (fr) * 2006-08-08 2008-02-27 AEterna Zentaris GmbH Utilisation de doses initiales d'analogues de LHRH et doses de maintenance d'antagonistes de LHRH pour le traitement de cancers dépendant des hormones
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
JP2010524996A (ja) * 2007-04-23 2010-07-22 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト Ｂｒｃａ媒介性疾患における使用のための、プロゲステロン受容体拮抗薬と、ルテインホルモン放出ホルモン作動薬および拮抗薬との組み合わせ
CN101775054B (zh) * 2010-02-05 2012-12-26 常州佳尔科药业集团有限公司 4-羟基-4-烯-3-酮甾族化合物的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9911582D0 (en) * 1999-05-18 1999-07-21 Pharmacia & Upjohn Spa Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0239995A2 *

Also Published As

Publication number Publication date
JP2004536022A (ja) 2004-12-02
EA200300572A1 (ru) 2004-06-24
WO2002039995A2 (fr) 2002-05-23
KR20030051828A (ko) 2003-06-25
CZ20031349A3 (cs) 2004-05-12
BR0115423A (pt) 2005-12-13
WO2002039995A3 (fr) 2003-05-01
ZA200303669B (en) 2004-05-13
NO20032206L (no) 2003-07-15
MXPA03004195A (es) 2003-09-22
PL365904A1 (en) 2005-01-10
NO20032206D0 (no) 2003-05-15
CN1498112A (zh) 2004-05-19
AU2002230464A1 (en) 2002-05-27
IL155817A0 (en) 2003-12-23
CA2428249A1 (fr) 2002-05-23
NZ525720A (en) 2006-12-22
WO2002039995A9 (fr) 2003-02-06

Similar Documents

Publication Publication Date Title
Felberbaum et al. Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix.
US7309691B2 (en) Combined pharmaceutical preparation containing LHRH-analogous substances and anti estrogens for treating gynaecological disorders
WO2000030674A1 (fr) Agents neuropeptide y-y4 utilises dans le traitement des troubles de la reproduction
Griesinger et al. GnRH-antagonists in reproductive medicine
Klijn et al. Anti-tumor and endocrine effects of chronic LHRH agonist treatment (buserelin) with or without tamoxifen in premenopausal metastatic breast cancer
EP1341549A2 (fr) Traitement combine de maladies dependantes des oestrogenes
Goldspiel et al. Goserelin acetate implant: a depot luteinizing hormone-releasing hormone analog for advanced prostate cancer
Klijn LH-RH agonists in the treatment of metastatic breast cancer: ten years’ experience
CN1137722C (zh) 为长期治疗方案确立基础(tonic)卵巢雌激素分泌
WO2002039996A2 (fr) Therapie combinee contre des tumeurs comprenant du phosphate d'estramustine et des agonistes ou antagonistes de lh-rh
US20040043938A1 (en) Combination therapy for estrogen-dependent disorders
US20120004182A1 (en) Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells
Savino et al. GnRH analogs in gynecological oncology: a review
Kotlyar et al. Eliminating hormones with orally active gonadotropin-releasing hormone antagonists
EP1029868A1 (fr) Remede contre les hysteromyomes, contenant du dienogeste comme principe actif
Fluker Gonadotropin-releasing hormone antagonists
Forti Clinicai applications of GnRH analogs
HK1066169A (en) Combination therapy for estrogen-dependent disorders
Adegoke et al. GnRH Antagonists in the Treatment of Uterine Fibroids
Engel et al. Luteinizing hormone-releasing hormone antagonists in gynecology
KR100210472B1 (ko) 황체형성 호르몬 분비 호르몬 길항 펩티드
HU199694B (en) Process for producing citostatic pharmaceutical compositions containing gonadoliberin derivatives
Klijn of Metastatic Breast Cancer: Ten Years' Experience
Foldesy et al. Role of adrenal androgens in prostate regression in rats treated with an antiandrogen and an LHRH agonist
Klijn et al. Long-term peptide hormone treatment with LHRH-agonists in metastatic breast cancer: a review

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030529

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: PHARMACIA & UPJOHN COMPANY LLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080602